Abstract
Get full access to this article
View all access options for this article.
References
1.Verve Therapeutics . Verve therapeutics announces updates on its PCSK9 program . April x 2024 . Available from: https://ir.vervetx.com/news-releases/news-release-details/verve-therapeutics-announces-updates-its-pcsk9-program [Last accessed:
April 11 , 2024
].
2.
Grinstein
J
. Bittersweet Symphony. Verve’s Pause on VERVE-101 Narrows LNP-Delivery Strategy . Genetic Engineering & Biotechnology News. April 5, 2024 . Available from: https://www.genengnews.com/topics/genome-editing/bittersweet-symphony-verves-pause-on-verve-101-narrows-lnp-delivery-strategy/ [Last accessed:
April , 11
].
3.United States Patent Application Publication . Pub. No. US2023/0227793 A1 . July 20, 2023 . Available from: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20230227793. [Last accessed:
April 9 , 2024
].
4.United States Patent Application Publication . Pub. No. US2022/0259617 A1 . August 18, 2022 . Available from: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20220259617 [Last accessed:
April 9 , 2024
].
5.
Philippidis
A
. Cloaking device: Liu, Joung Launch $100M Nvelop therapeutics to advance delivery of genetic cargo . Genetic Engineering & Biotechnology News. April 5, 2024 . Available from: https://www.genengnews.com/topics/genome-editing/cloaking-device-liu-joung-launch-100m-nvelop-therapeutics-to-advance-delivery-of-genetic-cargo/ [Last accessed:
April 11 , 2024
].
6.
Tanaka
Y
. Chinese scientist jailed for designer babies renews genome-editing research: Interview . Mainichi Shimbun, April 1, 2024 . Available from: https://mainichi.jp/english/articles/20240329/p2a/00m/0sc/050000c [Last accessed:
April , 11
].
7.
The CRISPR Journal
. Retraction of: Draft ethical principles for therapeutic assisted reproductive technologies by He, J et al., CRISPR J 2018; fast track ; doi: 10.1089/crispr.2018.0051 February 21, 2019 . Available from: https://www.liebertpub.com/doi/10.1089/crispr.2018.0051.retract [Last accessed:
April 11 , 2024
]
8.Intellia Therapeutics . Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy . March 18, 2024 . Available from: https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-patient-dosed-phase-3 [Last accessed:
April 11 , 2024
].
9.Ascend Advanced Therapies . Ascend acquires GMP manufacturing capacity in Alachua, Florida; Enters long-term partnership with Beacon Therapeutics for clinical and commercial AAV production . April 9, 2024 . Available from: https://www.beacontx.com/wp-content/uploads/2024/04/Ascend-acquisition-of-Beacon-MFG.pdf [Last accessed:
April 11 , 2024
].